Stream Biomedical was founded in 2016 to commercialize a novel biologic drug. To that end, Stream has assembled a team of seasoned biopharma R&D professionals.
Our drug, recombinant human Perlecan Domain V (rhPDV), exhibits significant neuroprotective and neuroreparative properties, resulting in dramatic functional improvement when administered after neurological injury. The initial target therapeutic indication for rhPDV is the treatment of acute ischemic stroke.
Stroke is one of the most debilitating conditions in human medicine. Only 10% of stroke survivors achieve full recovery, while over 40% are left with moderate to severe impairment, and 10% require long-term residential care. American Stroke Association
Recombinant Human Perlecan Domain V (rhPDV)
Perlecan is a large protein that is found in abundance in the extracellular matrix of many tissues and is a key component in the basement membranes of brain vasculature.
Perlecan consists of five domains (I-V). Research has shown that endogenous Perlecan Domain V (PDV) is actively generated in response to vigorous physical activity and trauma, including traumatic brain injury (TBI) & stroke. PDV is a critical component of the body’s attempt at post-stroke cerebrovascular self-repair.
Our rhPDV drug has been shown in preclinical studies to be neuroprotective; in other words, the molecule protects brain cells and limits the effects of injury once administered.
rhPDV has also been shown to support neurological repair in vivo; it is both angiogenic (helps create new cerebral blood vessels) and neurogenic (helps proliferate new “baby” neurons in the brain and fosters them to become functional “adult” neurons).
Most importantly, rhPDV elicits significant post-acute recovery in both stroke and TBI preclinical models.